But a US adcom slams Amgen’s oversight of Codebreak-200, as the group’s KRAS rival Mirati surges on takeover talk.

But Repare and Black Diamond still have rebuilding to do.

After Exkivity signals another accelerated approval slowdown the Amgen drug tomorrow faces an adcom over its own conditional approval.

Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.

Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.

With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.

Mirati raises $300m as its chief exec departs. What’s not to like?